J. Goldman & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

J. Goldman & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,300	Closed	-$1.67M	–	473
2024 Q2	$1.67M	Buy	+20,300	New	+$1.69M	0.05%	261
2023 Q3	–	Sell	-17,500	Closed	-$1.52M	–	374
2023 Q2	$1.52M	Buy	+17,500	New	+$1.65M	0.06%	227
2021 Q1	–	Sell	-84,000	Closed	-$7.37M	–	441
2020 Q4	$7.37M	Buy	+84,000	New	+$6.66M	0.37%	78
2016 Q2	–	Sell	-15,000	Closed	-$1.24M	–	332
2016 Q1	$1.24M	Buy	+15,000	New	+$1.22M	0.08%	213

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

J. Goldman & Co's BMRN Position: Q3 2024 in Review

J. Goldman & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 31,701 shares — an estimated $2.61M sold.

J. Goldman & Co first reported a position in BMRN in Q1 2016 and held it in 7 quarters. The position peaked at $11.6M in Q1 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

J. Goldman & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
J. Goldman & Co sold 31,701 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.61M.
J. Goldman & Co first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 7 quarters.
J. Goldman & Co's BioMarin Pharmaceuticals position peaked at $11.6M in Q1 2024.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.